EMS PRO INDUSTRY NEWS
Carlson and Neul Announce Global Partnership
Carlson and Neul recently announced plans to jointly develop and market a new white space radio networking system aimed at bringing affordable broadband to millions around the world. This marks the beginning of a significant, global partnership between two established leaders in white space technologies. The Neul/Carlson system will give broadband users access to more than 200MHz of high-quality white space radio spectrum. Volume shipments of the new system are planned before the end of 2011, with samples and develop- ment equipment available before then. Carlson and Neul are committed to working closely with wireless Internet service providers (WISPs) and others to bring affordable broadband connectivity to under-served regions around the globe. This groundbreaking technology uses ‘white spaces,’ or unused portions, of UHF spectrum for broadband. Thanks to its outstanding propagation characteristics, UHF signal can travel through walls and other obstacles: Line of sight is not needed to the subscriber’s home. As a result, WISPs using the new system can deliver faster, more reliable service to more cus- tomers with the same network infrastruc- ture, driving additional revenue. “Broadband is a global necessity in today’s world, and we see this partner- ship as a leap forward for rural broad- band worldwide,” said Carlson CEO James Carlson. “White space technology is especially effective in sparsely populat- ed areas and rugged terrain, giv- ing rural communities real- time access to the business opportunities and educational resources the Internet has to offer,” Carlson added. “Millions of people
around the world do not currently have access to decent broadband at affordable prices,” commented Luke D’Arcy, VP of Marketing at Neul. “The technology Neul and Carlson are developing together gives Internet service providers the means to serve more customers with a quality broadband service, particularly in rural locations, through white space’s long range, low cost and excellent propa- gation characteristics,” explained D’Arcy. Carlson and Neul are combining their strengths to deliver a high-bandwidth product that offers unrivalled range and signal penetration. This revolutionary product is designed for use in the U.S., U.K. and beyond. With approval from both the Federal Communications Commission (FCC) and Ofcom (the U.K.’s spectrum regulatory entity), the companies plan to introduce the prod- uct to the open market by year’s end. White space technology is also applica- ble to a variety of other use cases, including in low-data-rate, even longer- range machine-to-machine (M2M) communications.
Both Carlson and Neul have been at the forefront of the white space radio revolu- tion internationally, with active trials in the U.S. and the U.K. Carlson was one of the first to implement successful TV white space-based broadband systems under experimental license, most notably on Native American reservations. EMS
Approves Xarelto
The U.S. Food and Drug Administration today approved the anti-clotting drug Xarelto (rivaroxaban) to reduce the risk of stroke in people who have abnormal heart rhythm (non-valvular atrial fibrillation). Atrial fibrillation occurs in more than two million Americans and is one of the most common types of abnormal heart rhythm. In atrial fibrillation, the beating of the heart’s two upper heart chambers (atria) is irregular and poorly coordinat- ed. This leads to blood pooling in these chambers, resulting in blood clots. Non- valvular atrial fibrillation refers to atrial fibrillation in patients who do not have significant problems in their heart valves. “Atrial fibrillation can lead to the forma- tion of blood clots, which can travel to the brain, blocking blood flow and causing a disabling stroke,” said Norman Stockbridge, M.D., Ph.D., director of the Division of Cardiovascular and Renal Products in the FDA’s Center for Drug Evaluation and Research. “This approval gives doctors and patients another treat- ment option for a condition that must be managed carefully,” Stockbridge explained. A stroke occurs if the flow of blood to a portion of the brain is blocked. If brain cells die or are damaged because of a stroke, symptoms occur in the parts of the body that these brain cells control. Stroke symptoms include sudden weak- ness; paralysis or numbness of the face, arms, or legs; trouble speaking or under- standing speech; and trouble seeing. The safety and efficacy of Xarelto were evalu- ated in a clinical trial with more than 14,000 patients comparing Xarelto with the anti-clotting drug warfarin. In the trial, Xarelto was similar to warfarin in its ability to prevent stroke. For people tak- ing the drug for atrial fibrillation, Xarelto should be taken one time a day with the evening meal so that it will be completely absorbed. EMS
6 December 2011
FDA
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36